Review



rhtrail  (R&D Systems)


Bioz Verified Symbol R&D Systems is a verified supplier
Bioz Manufacturer Symbol R&D Systems manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 94
      Buy from Supplier

    Structured Review

    R&D Systems rhtrail
    Figure 1. <t>rhTRAIL</t> exposure effect alone and in combination with WT HSV-1 virus on HNSCC cell lines and the normal cell line, HaCaT. Treatment was performed with rhTRAIL at 100 ng/mL and in combination with WT HSV-1 virus at MOI 0f. 0.2 and 1.0. Cell viability analysis after 48 (A) and 72 h (B) of exposure. Results are expressed by mean percentage ± standard deviation of cell viability relative to PBS 1X (considering 100% viability). Data represent the average of three independent assays performed in triplicate. The asterisks indicate statistical significance (*P < 0.05; **P < 0.01; ***P < 0.001) in the comparison with the experimental groups by non-normal distribution Kruskal–Wallis test.
    Rhtrail, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 132 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+human+trail+(rhtrail/Recombinant+Human+TRAIL%2FTNFSF10+Protein/pm37865660-166-10-12
    Average 94 stars, based on 132 article reviews
    rhtrail - by Bioz Stars, 2026-09
    94/100 stars

    Images

    1) Product Images from "Combined effect of the pro-apoptotic rhTRAIL protein and HSV-1 virus in head and neck cancer cell lines."

    Article Title: Combined effect of the pro-apoptotic rhTRAIL protein and HSV-1 virus in head and neck cancer cell lines.

    Journal: Scientific reports

    doi: 10.1038/s41598-023-44888-9

    Figure 1. rhTRAIL exposure effect alone and in combination with WT HSV-1 virus on HNSCC cell lines and the normal cell line, HaCaT. Treatment was performed with rhTRAIL at 100 ng/mL and in combination with WT HSV-1 virus at MOI 0f. 0.2 and 1.0. Cell viability analysis after 48 (A) and 72 h (B) of exposure. Results are expressed by mean percentage ± standard deviation of cell viability relative to PBS 1X (considering 100% viability). Data represent the average of three independent assays performed in triplicate. The asterisks indicate statistical significance (*P < 0.05; **P < 0.01; ***P < 0.001) in the comparison with the experimental groups by non-normal distribution Kruskal–Wallis test.
    Figure Legend Snippet: Figure 1. rhTRAIL exposure effect alone and in combination with WT HSV-1 virus on HNSCC cell lines and the normal cell line, HaCaT. Treatment was performed with rhTRAIL at 100 ng/mL and in combination with WT HSV-1 virus at MOI 0f. 0.2 and 1.0. Cell viability analysis after 48 (A) and 72 h (B) of exposure. Results are expressed by mean percentage ± standard deviation of cell viability relative to PBS 1X (considering 100% viability). Data represent the average of three independent assays performed in triplicate. The asterisks indicate statistical significance (*P < 0.05; **P < 0.01; ***P < 0.001) in the comparison with the experimental groups by non-normal distribution Kruskal–Wallis test.

    Techniques Used: Virus, Standard Deviation, Comparison

    Figure 2. Expression analysis of apoptosis-associated proteins in the HCB289 cell line after 24 h of exposure with rhTRAIL ligand, WT HSV-1 and in combination. (A) and (B) detection and quantification of proteins after treatment. Results are expressed as mean percentage ± standard deviation of relative expression of cleaved protein relative to control (considering 100% expression) and normalized by the portion of total protein (non- cleaved). Data represent the average of three independent assays. The asterisks indicate statistical significance (*P < 0.05; **P < 0.01; ***P < 0.001) in the comparison with the experimental groups by one-way ANOVA. Raw blots are presented in Supplementary Data 1.
    Figure Legend Snippet: Figure 2. Expression analysis of apoptosis-associated proteins in the HCB289 cell line after 24 h of exposure with rhTRAIL ligand, WT HSV-1 and in combination. (A) and (B) detection and quantification of proteins after treatment. Results are expressed as mean percentage ± standard deviation of relative expression of cleaved protein relative to control (considering 100% expression) and normalized by the portion of total protein (non- cleaved). Data represent the average of three independent assays. The asterisks indicate statistical significance (*P < 0.05; **P < 0.01; ***P < 0.001) in the comparison with the experimental groups by one-way ANOVA. Raw blots are presented in Supplementary Data 1.

    Techniques Used: Expressing, Standard Deviation, Control, Comparison

    Figure 3. Expression analysis of apoptosis-associated proteins in the UD-SCC-2 cell line after 24 h of exposure with rhTRAIL ligand, WT HSV-1 and in combination. (A) and (B) detection and quantification of proteins after treatment. Results are expressed as mean percentage ± standard deviation of relative expression of cleaved protein relative to control (considering 100% expression) and normalized by the portion of total protein (non- cleaved). Data represent the average of three independent assays. The asterisks indicate statistical significance (*P < 0.05; **P < 0.01; ***P < 0.001) in the comparison with the experimental groups by one-way ANOVA. Raw blots are presented in Supplementary Data 2.
    Figure Legend Snippet: Figure 3. Expression analysis of apoptosis-associated proteins in the UD-SCC-2 cell line after 24 h of exposure with rhTRAIL ligand, WT HSV-1 and in combination. (A) and (B) detection and quantification of proteins after treatment. Results are expressed as mean percentage ± standard deviation of relative expression of cleaved protein relative to control (considering 100% expression) and normalized by the portion of total protein (non- cleaved). Data represent the average of three independent assays. The asterisks indicate statistical significance (*P < 0.05; **P < 0.01; ***P < 0.001) in the comparison with the experimental groups by one-way ANOVA. Raw blots are presented in Supplementary Data 2.

    Techniques Used: Expressing, Standard Deviation, Control, Comparison

    Figure 4. Expression analysis of apoptosis-associated proteins in the HCB289 cell line after 48 h of exposure with rhTRAIL ligand, WT HSV-1 and in combination. (A) and (B) detection and quantification of proteins after treatment. Results are expressed as mean percentage ± standard deviation of relative expression of cleaved protein relative to control (considering 100% expression) and normalized by the portion of total protein (non- cleaved). Data represent the average of two independent assays. The asterisks indicate statistical significance (*P < 0.05) in the comparison with the experimental groups by one-way ANOVA. Raw blots are presented in Supplementary Data 3.
    Figure Legend Snippet: Figure 4. Expression analysis of apoptosis-associated proteins in the HCB289 cell line after 48 h of exposure with rhTRAIL ligand, WT HSV-1 and in combination. (A) and (B) detection and quantification of proteins after treatment. Results are expressed as mean percentage ± standard deviation of relative expression of cleaved protein relative to control (considering 100% expression) and normalized by the portion of total protein (non- cleaved). Data represent the average of two independent assays. The asterisks indicate statistical significance (*P < 0.05) in the comparison with the experimental groups by one-way ANOVA. Raw blots are presented in Supplementary Data 3.

    Techniques Used: Expressing, Standard Deviation, Control, Comparison

    Figure 5. Expression analysis of apoptosis-associated proteins in the UD-SCC-2 cell line after 48 h of exposure with rhTRAIL ligand, WT HSV-1 and in combination. (A) and (B) detection and quantification of proteins after treatment. Results are expressed as mean percentage ± standard deviation of relative expression of cleaved protein relative to control (considering 100% expression) and normalized by the portion of total protein (non- cleaved). Data represent the average of two independent assays. The asterisks indicate statistical significance (*P < 0.05) in the comparison with the experimental groups by one-way ANOVA. Raw blots are presented in Supplementary Data 4.
    Figure Legend Snippet: Figure 5. Expression analysis of apoptosis-associated proteins in the UD-SCC-2 cell line after 48 h of exposure with rhTRAIL ligand, WT HSV-1 and in combination. (A) and (B) detection and quantification of proteins after treatment. Results are expressed as mean percentage ± standard deviation of relative expression of cleaved protein relative to control (considering 100% expression) and normalized by the portion of total protein (non- cleaved). Data represent the average of two independent assays. The asterisks indicate statistical significance (*P < 0.05) in the comparison with the experimental groups by one-way ANOVA. Raw blots are presented in Supplementary Data 4.

    Techniques Used: Expressing, Standard Deviation, Control, Comparison

    Figure 6. Flow cytometry apoptosis analysis after treatment with rhTRAIL ligand, WT HSV-1 and in combination. A and B) Analysis of HCB289 cell line after 24 and 48 h of treatment exposure. C and D) Analysis of UD-SCC-2 cell line after 24 and 48 h of treatment exposure. Results are expressed as mean percentage ± standard deviation of the cell death rate. Data represent the average of three independent assays. The asterisks indicate statistical significance (*P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.001) in the comparison with the experimental groups by one-way ANOVA.
    Figure Legend Snippet: Figure 6. Flow cytometry apoptosis analysis after treatment with rhTRAIL ligand, WT HSV-1 and in combination. A and B) Analysis of HCB289 cell line after 24 and 48 h of treatment exposure. C and D) Analysis of UD-SCC-2 cell line after 24 and 48 h of treatment exposure. Results are expressed as mean percentage ± standard deviation of the cell death rate. Data represent the average of three independent assays. The asterisks indicate statistical significance (*P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.001) in the comparison with the experimental groups by one-way ANOVA.

    Techniques Used: Flow Cytometry, Standard Deviation, Comparison

    Figure 7. DR-5 expression analysis in the HCB289 cell line after treatment with rhTRAIL ligand, WT-HSV-1 and combination. (A) and (B) Detection and quantification of the receptor after 24 h of exposure treatment. (C) and (D) Detection and quantification of the receptor after 48 h of exposure treatment. Results are expressed as mean percentage ± standard deviation of relative expression of cleaved protein relative to control (considering 100% expression) and normalized by the protein α-tubulin. Data represent the average of two independent. Raw blots are presented in Supplementary Data 5.
    Figure Legend Snippet: Figure 7. DR-5 expression analysis in the HCB289 cell line after treatment with rhTRAIL ligand, WT-HSV-1 and combination. (A) and (B) Detection and quantification of the receptor after 24 h of exposure treatment. (C) and (D) Detection and quantification of the receptor after 48 h of exposure treatment. Results are expressed as mean percentage ± standard deviation of relative expression of cleaved protein relative to control (considering 100% expression) and normalized by the protein α-tubulin. Data represent the average of two independent. Raw blots are presented in Supplementary Data 5.

    Techniques Used: Expressing, Standard Deviation, Control

    Figure 8. DR-5 expression analysis in the UD-SCC-2 cell line after treatment with rhTRAIL ligand, WT-HSV-1 and combination. (A) and (B) Detection and quantification of the receptor after 24 h of exposure treatment. (C) and (D) Detection and quantification of the receptor after 48 h of exposure treatment. Results are expressed as mean percentage ± standard deviation of relative expression of cleaved protein relative to control (considering 100% expression) and normalized by the protein α-tubulin. Data represent the average of two independent assays. Raw blots are presented in Supplementary Data 6.
    Figure Legend Snippet: Figure 8. DR-5 expression analysis in the UD-SCC-2 cell line after treatment with rhTRAIL ligand, WT-HSV-1 and combination. (A) and (B) Detection and quantification of the receptor after 24 h of exposure treatment. (C) and (D) Detection and quantification of the receptor after 48 h of exposure treatment. Results are expressed as mean percentage ± standard deviation of relative expression of cleaved protein relative to control (considering 100% expression) and normalized by the protein α-tubulin. Data represent the average of two independent assays. Raw blots are presented in Supplementary Data 6.

    Techniques Used: Expressing, Standard Deviation, Control

    Related Articles

    Recombinant:

    Article Title: Accumulation of autophagosomes in breast cancer cells induces TRAIL resistance through downregulation of surface expression of death receptors 4 and 5
    Article Snippet: All the cell lines were cultured per ATCC recommendations and tested to be free of mycoplasma contamination at receiving and on a monthly basis. .. Recombinant human TRAIL (rhTRAIL) (R & D systems, 375-TEC) which contains 168 amino acids corresponding to the extracellular domain of human TRAIL (Val114–Gly281) was expressed by Escherichia coli and purified as a homotrimeric protein. .. 3-methyladenine (3-MA, M9281), a general inhibitor of autophagy, and anti-β-actin antibody (A2066) were purchased from Sigma-Aldrich.

    Article Title: Circulating Tumor Cells Develop Resistance to TRAIL-Induced Apoptosis through Autophagic Removal of Death Receptor 5: Evidence from an <em>In Vitro</em> Model
    Article Snippet: .. Cells were treated with 283 recombinant human TRAIL (rhTRAIL) (R&D Systems, 375-TEC) at two different doses (10 ng/mL 284 and 100 ng/mL for MDA-MB-231 and ZR75-1 cell lines; 50 ng/mL and 500 ng/mL for MCF7 cell lines). ..

    Article Title: Accumulation of autophagosomes in breast cancer cells induces TRAIL resistance through downregulation of surface expression of death receptors 4 and 5.
    Article Snippet: All the cell lines were cultured per ATCC recommendations and tested to be free of mycoplasma contamination at receiving and on a monthly basis. .. Recombinant human TRAIL (rhTRAIL) (R & D systems, 375-TEC) which contains 168 amino acids corresponding to the extracellular domain of human TRAIL (Val114–Gly281) was expressed by Escherichia coli and purified as a homotrimeric protein. .. 3-methyladenine (3-MA, M9281), a general inhibitor of autophagy, and anti-β-actin antibody (A2066) were purchased from Sigma-Aldrich.

    Article Title: TRAIL in Combination with Subtoxic 5-FU Effectively Inhibit Cell Proliferation and Induce Apoptosis in Cholangiocarcinoma Cells.
    Article Snippet: 5-FU was purchased from Pharmachemie BV (Haarlem, Netherlands) and freshly prepared by diluting with culture medium to reach the optimal concentration before use. .. Recombinant human TRAIL (rhTRAIL) was purchased from R&D Systems (Minneapolis, MN) and prepared as a stock solution (100 μg/ml) in sterile PBS with 0.1% bovine serum albumin and stored at -70°C until use. .. RNA isolation and semi-quantitative reverse transcriptionpolymerase chain reaction (RT-PCR) RNA was extracted from all cell lines using SV Total RNA Isolation System (Promega Corporation, Madison, WI).

    Article Title: TRAIL induces endocytosis of its death receptors in MDA-MB-231 breast cancer cells.
    Article Snippet: Human breast cancer cell lines MDA-MB-231 and BT474 were obtained from the American Type Culture Collection (ATCC) and cultured under the recommended conditions. .. Recombinant human TRAIL (rhTRAIL) expressed and purified as homotrimeric protein from E. coli, and monoclonal antibodies specific to TRAIL death receptor-4 (AF347) and -5 (MAB6312) and their phycoerythrin (PE)-conjugated forms were purchased from R&D Systems (Minneapolis, MN). .. PE-conjugated monoclonal antiTRAIL antibody (RIK-2) was from Abcam (Cambridge, MA).

    Article Title: Downregulation of DcR3 sensitizes hepatocellular carcinoma cells to TRAIL-induced apoptosis
    Article Snippet: .. Cells were maintained in Dulbecco’s Modified Eagle’s Medium supplemented with 10% fetal bovine serum (Gibco, Waltham, MA, USA), 100 U/mL penicillin, and 100 μg/mL streptomycin (Invitrogen, Carlsbad, CA, USA) in 5% CO 2 at 37°C. antibodies and reagents DcR3 polyclonal antibody, recombinant human TRAIL (rhTRAIL), and neutralizing antibodies against TRAIL-R1 (DR4) and TRAIL-R2 (DR5) were purchased from R&D Systems (Minneapolis, MN, USA). .. Rat monoclonal antibodies against Mcl-1, Bcl-XL, Bax, survivin, IAP-2, DR4, DR5, and GAPDH were purchased from Abcam (Shanghai, People’s Republic of China).

    Purification:

    Article Title: Accumulation of autophagosomes in breast cancer cells induces TRAIL resistance through downregulation of surface expression of death receptors 4 and 5
    Article Snippet: All the cell lines were cultured per ATCC recommendations and tested to be free of mycoplasma contamination at receiving and on a monthly basis. .. Recombinant human TRAIL (rhTRAIL) (R & D systems, 375-TEC) which contains 168 amino acids corresponding to the extracellular domain of human TRAIL (Val114–Gly281) was expressed by Escherichia coli and purified as a homotrimeric protein. .. 3-methyladenine (3-MA, M9281), a general inhibitor of autophagy, and anti-β-actin antibody (A2066) were purchased from Sigma-Aldrich.

    Article Title: Accumulation of autophagosomes in breast cancer cells induces TRAIL resistance through downregulation of surface expression of death receptors 4 and 5.
    Article Snippet: All the cell lines were cultured per ATCC recommendations and tested to be free of mycoplasma contamination at receiving and on a monthly basis. .. Recombinant human TRAIL (rhTRAIL) (R & D systems, 375-TEC) which contains 168 amino acids corresponding to the extracellular domain of human TRAIL (Val114–Gly281) was expressed by Escherichia coli and purified as a homotrimeric protein. .. 3-methyladenine (3-MA, M9281), a general inhibitor of autophagy, and anti-β-actin antibody (A2066) were purchased from Sigma-Aldrich.

    Article Title: TRAIL induces endocytosis of its death receptors in MDA-MB-231 breast cancer cells.
    Article Snippet: Human breast cancer cell lines MDA-MB-231 and BT474 were obtained from the American Type Culture Collection (ATCC) and cultured under the recommended conditions. .. Recombinant human TRAIL (rhTRAIL) expressed and purified as homotrimeric protein from E. coli, and monoclonal antibodies specific to TRAIL death receptor-4 (AF347) and -5 (MAB6312) and their phycoerythrin (PE)-conjugated forms were purchased from R&D Systems (Minneapolis, MN). .. PE-conjugated monoclonal antiTRAIL antibody (RIK-2) was from Abcam (Cambridge, MA).

    Multiple Displacement Amplification:

    Article Title: Circulating Tumor Cells Develop Resistance to TRAIL-Induced Apoptosis through Autophagic Removal of Death Receptor 5: Evidence from an <em>In Vitro</em> Model
    Article Snippet: .. Cells were treated with 283 recombinant human TRAIL (rhTRAIL) (R&D Systems, 375-TEC) at two different doses (10 ng/mL 284 and 100 ng/mL for MDA-MB-231 and ZR75-1 cell lines; 50 ng/mL and 500 ng/mL for MCF7 cell lines). ..

    Sterility:

    Article Title: TRAIL in Combination with Subtoxic 5-FU Effectively Inhibit Cell Proliferation and Induce Apoptosis in Cholangiocarcinoma Cells.
    Article Snippet: 5-FU was purchased from Pharmachemie BV (Haarlem, Netherlands) and freshly prepared by diluting with culture medium to reach the optimal concentration before use. .. Recombinant human TRAIL (rhTRAIL) was purchased from R&D Systems (Minneapolis, MN) and prepared as a stock solution (100 μg/ml) in sterile PBS with 0.1% bovine serum albumin and stored at -70°C until use. .. RNA isolation and semi-quantitative reverse transcriptionpolymerase chain reaction (RT-PCR) RNA was extracted from all cell lines using SV Total RNA Isolation System (Promega Corporation, Madison, WI).

    Bioprocessing:

    Article Title: TRAIL induces endocytosis of its death receptors in MDA-MB-231 breast cancer cells.
    Article Snippet: Human breast cancer cell lines MDA-MB-231 and BT474 were obtained from the American Type Culture Collection (ATCC) and cultured under the recommended conditions. .. Recombinant human TRAIL (rhTRAIL) expressed and purified as homotrimeric protein from E. coli, and monoclonal antibodies specific to TRAIL death receptor-4 (AF347) and -5 (MAB6312) and their phycoerythrin (PE)-conjugated forms were purchased from R&D Systems (Minneapolis, MN). .. PE-conjugated monoclonal antiTRAIL antibody (RIK-2) was from Abcam (Cambridge, MA).

    Modification:

    Article Title: Downregulation of DcR3 sensitizes hepatocellular carcinoma cells to TRAIL-induced apoptosis
    Article Snippet: .. Cells were maintained in Dulbecco’s Modified Eagle’s Medium supplemented with 10% fetal bovine serum (Gibco, Waltham, MA, USA), 100 U/mL penicillin, and 100 μg/mL streptomycin (Invitrogen, Carlsbad, CA, USA) in 5% CO 2 at 37°C. antibodies and reagents DcR3 polyclonal antibody, recombinant human TRAIL (rhTRAIL), and neutralizing antibodies against TRAIL-R1 (DR4) and TRAIL-R2 (DR5) were purchased from R&D Systems (Minneapolis, MN, USA). .. Rat monoclonal antibodies against Mcl-1, Bcl-XL, Bax, survivin, IAP-2, DR4, DR5, and GAPDH were purchased from Abcam (Shanghai, People’s Republic of China).



    Similar Products

    recombinant human trail rhtrail cat# 310-04  (PeproTech)
    90
    PeproTech recombinant human trail rhtrail cat# 310-04
    Recombinant Human Trail Rhtrail Cat# 310 04, supplied by PeproTech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+human+trail+(rhtrail/m+csf+cat+310+01+1mg/pm40247082-48-0-14
    Average 90 stars, based on 1 article reviews
    recombinant human trail rhtrail cat# 310-04 - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    rhtrail recombinant human trail  (Merck KGaA)
    90
    Merck KGaA rhtrail recombinant human trail
    Rhtrail Recombinant Human Trail, supplied by Merck KGaA, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+human+trail+(rhtrail/recombinant+trail/pm39392552-44-6-10
    Average 90 stars, based on 1 article reviews
    rhtrail recombinant human trail - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    rhtrail  (R&D Systems)
    94
    R&D Systems rhtrail
    Figure 1. <t>rhTRAIL</t> exposure effect alone and in combination with WT HSV-1 virus on HNSCC cell lines and the normal cell line, HaCaT. Treatment was performed with rhTRAIL at 100 ng/mL and in combination with WT HSV-1 virus at MOI 0f. 0.2 and 1.0. Cell viability analysis after 48 (A) and 72 h (B) of exposure. Results are expressed by mean percentage ± standard deviation of cell viability relative to PBS 1X (considering 100% viability). Data represent the average of three independent assays performed in triplicate. The asterisks indicate statistical significance (*P < 0.05; **P < 0.01; ***P < 0.001) in the comparison with the experimental groups by non-normal distribution Kruskal–Wallis test.
    Rhtrail, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+human+trail+(rhtrail/Recombinant+Human+TRAIL%2FTNFSF10+Protein/pm37865660-166-10-12
    Average 94 stars, based on 1 article reviews
    rhtrail - by Bioz Stars, 2026-09
    94/100 stars
    		  Buy from Supplier
    rhtrail  (R&D Systems Hematology)
    94
    R&D Systems Hematology rhtrail
    IFNα is cytotoxic to a subset of bladder cancer cell lines in multiple contexts (A) Schematic of adenoviral tool vectors. The Ad-IFNα2b vector includes hIFNα2b driven by a CMV promoter inserted into the E1 region and GFP driven by the RSV promoter inserted into the E3 region. The Ad-GFP vector includes an empty E1 region and GFP driven by the RSV promoter inserted into the E3 region. Both tool viruses lack viral E1 and E3. (B–G) Cells were exposed to (B) 100,000 U/mL rhIFNα2b, (C) 50 ng/mL TRAIL, (D) Ad-IFNα2b (MOI = 100), (E) Ad-GFP (MOI = 100) and conditioned media (CM) produced by (F) Ad-IFNα2b or (G) Ad-GFP transduced SV-HUC-1 cells. Cytotoxicity is reported as the relative fraction of dead cells after 48 h of treatment. Results are presented as mean ± SD from independent experiments performed in triplicate; N = 2 or 3 for Ad-GFP, N = 3 for all other treatments. (H) Pairwise correlation analysis was performed for all treatments and the Pearson correlation coefficient was determined. Bold indicates P < 0.05. (I) Cells were exposed to Ad-IFNα2b, Ad-GFP, or Ad-empty (MOI = 100 for all); cytotoxicity is reported as the relative fraction of dead cells after 48 h of treatment. Ad, adenovirus vector; CMV, cytomegalovirus; GFP, green fluorescent protein; rhIFNα2b, recombinant human interferon alpha 2b, <t>rhTRAIL,</t> recombinant human TNF-related apoptosis-inducing ligand; RSV, respiratory syncytial virus; SV40 Poly(A), simian virus 40 polyadenylated tail.
    Rhtrail, supplied by R&D Systems Hematology, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+human+trail+(rhtrail/Recombinant+Human+TRAIL%2FTNFSF10+Protein/pmc08645427-199-17-18
    Average 94 stars, based on 1 article reviews
    rhtrail - by Bioz Stars, 2026-09
    94/100 stars
    		  Buy from Supplier
    human recombinant trail protein rhtrail  (R&D Systems)
    94
    R&D Systems human recombinant trail protein rhtrail
    IFNα is cytotoxic to a subset of bladder cancer cell lines in multiple contexts (A) Schematic of adenoviral tool vectors. The Ad-IFNα2b vector includes hIFNα2b driven by a CMV promoter inserted into the E1 region and GFP driven by the RSV promoter inserted into the E3 region. The Ad-GFP vector includes an empty E1 region and GFP driven by the RSV promoter inserted into the E3 region. Both tool viruses lack viral E1 and E3. (B–G) Cells were exposed to (B) 100,000 U/mL rhIFNα2b, (C) 50 ng/mL TRAIL, (D) Ad-IFNα2b (MOI = 100), (E) Ad-GFP (MOI = 100) and conditioned media (CM) produced by (F) Ad-IFNα2b or (G) Ad-GFP transduced SV-HUC-1 cells. Cytotoxicity is reported as the relative fraction of dead cells after 48 h of treatment. Results are presented as mean ± SD from independent experiments performed in triplicate; N = 2 or 3 for Ad-GFP, N = 3 for all other treatments. (H) Pairwise correlation analysis was performed for all treatments and the Pearson correlation coefficient was determined. Bold indicates P < 0.05. (I) Cells were exposed to Ad-IFNα2b, Ad-GFP, or Ad-empty (MOI = 100 for all); cytotoxicity is reported as the relative fraction of dead cells after 48 h of treatment. Ad, adenovirus vector; CMV, cytomegalovirus; GFP, green fluorescent protein; rhIFNα2b, recombinant human interferon alpha 2b, <t>rhTRAIL,</t> recombinant human TNF-related apoptosis-inducing ligand; RSV, respiratory syncytial virus; SV40 Poly(A), simian virus 40 polyadenylated tail.
    Human Recombinant Trail Protein Rhtrail, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+human+trail+(rhtrail/Recombinant+Human+TRAIL%2FTNFSF10+Protein%2C+CF/pmc07407704-53-3-11
    Average 94 stars, based on 1 article reviews
    human recombinant trail protein rhtrail - by Bioz Stars, 2026-09
    94/100 stars
    		  Buy from Supplier
    recombinant human rhtrail r2 tnfrsf10b fc chimera protein  (R&D Systems)
    93
    R&D Systems recombinant human rhtrail r2 tnfrsf10b fc chimera protein
    IFNα is cytotoxic to a subset of bladder cancer cell lines in multiple contexts (A) Schematic of adenoviral tool vectors. The Ad-IFNα2b vector includes hIFNα2b driven by a CMV promoter inserted into the E1 region and GFP driven by the RSV promoter inserted into the E3 region. The Ad-GFP vector includes an empty E1 region and GFP driven by the RSV promoter inserted into the E3 region. Both tool viruses lack viral E1 and E3. (B–G) Cells were exposed to (B) 100,000 U/mL rhIFNα2b, (C) 50 ng/mL TRAIL, (D) Ad-IFNα2b (MOI = 100), (E) Ad-GFP (MOI = 100) and conditioned media (CM) produced by (F) Ad-IFNα2b or (G) Ad-GFP transduced SV-HUC-1 cells. Cytotoxicity is reported as the relative fraction of dead cells after 48 h of treatment. Results are presented as mean ± SD from independent experiments performed in triplicate; N = 2 or 3 for Ad-GFP, N = 3 for all other treatments. (H) Pairwise correlation analysis was performed for all treatments and the Pearson correlation coefficient was determined. Bold indicates P < 0.05. (I) Cells were exposed to Ad-IFNα2b, Ad-GFP, or Ad-empty (MOI = 100 for all); cytotoxicity is reported as the relative fraction of dead cells after 48 h of treatment. Ad, adenovirus vector; CMV, cytomegalovirus; GFP, green fluorescent protein; rhIFNα2b, recombinant human interferon alpha 2b, <t>rhTRAIL,</t> recombinant human TNF-related apoptosis-inducing ligand; RSV, respiratory syncytial virus; SV40 Poly(A), simian virus 40 polyadenylated tail.
    Recombinant Human Rhtrail R2 Tnfrsf10b Fc Chimera Protein, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+human+trail+(rhtrail/Recombinant+Human+TRAIL+R2%2FTNFRSF10B+Fc+Chimera+Protein%2C+CF/pmc07215742-212-36-45
    Average 93 stars, based on 1 article reviews
    recombinant human rhtrail r2 tnfrsf10b fc chimera protein - by Bioz Stars, 2026-09
    93/100 stars
    		  Buy from Supplier

    Image Search Results


    Figure 1. rhTRAIL exposure effect alone and in combination with WT HSV-1 virus on HNSCC cell lines and the normal cell line, HaCaT. Treatment was performed with rhTRAIL at 100 ng/mL and in combination with WT HSV-1 virus at MOI 0f. 0.2 and 1.0. Cell viability analysis after 48 (A) and 72 h (B) of exposure. Results are expressed by mean percentage ± standard deviation of cell viability relative to PBS 1X (considering 100% viability). Data represent the average of three independent assays performed in triplicate. The asterisks indicate statistical significance (*P < 0.05; **P < 0.01; ***P < 0.001) in the comparison with the experimental groups by non-normal distribution Kruskal–Wallis test.

    Journal: Scientific reports

    Article Title: Combined effect of the pro-apoptotic rhTRAIL protein and HSV-1 virus in head and neck cancer cell lines.

    doi: 10.1038/s41598-023-44888-9

    Figure Lengend Snippet: Figure 1. rhTRAIL exposure effect alone and in combination with WT HSV-1 virus on HNSCC cell lines and the normal cell line, HaCaT. Treatment was performed with rhTRAIL at 100 ng/mL and in combination with WT HSV-1 virus at MOI 0f. 0.2 and 1.0. Cell viability analysis after 48 (A) and 72 h (B) of exposure. Results are expressed by mean percentage ± standard deviation of cell viability relative to PBS 1X (considering 100% viability). Data represent the average of three independent assays performed in triplicate. The asterisks indicate statistical significance (*P < 0.05; **P < 0.01; ***P < 0.001) in the comparison with the experimental groups by non-normal distribution Kruskal–Wallis test.

    Article Snippet: :(0123456789) Scientific Reports | (2023) 13:18023 | https://doi.org/10.1038/s41598-023-44888-9 treated with rhTRAIL (#375-TL, R&D Systems, Minneapolis, MN, EUA) at 100 ng/mL, HSV-1 MOI 0.2 and/ or HSV-1 MOI 1.

    Techniques: Virus, Standard Deviation, Comparison

    Figure 2. Expression analysis of apoptosis-associated proteins in the HCB289 cell line after 24 h of exposure with rhTRAIL ligand, WT HSV-1 and in combination. (A) and (B) detection and quantification of proteins after treatment. Results are expressed as mean percentage ± standard deviation of relative expression of cleaved protein relative to control (considering 100% expression) and normalized by the portion of total protein (non- cleaved). Data represent the average of three independent assays. The asterisks indicate statistical significance (*P < 0.05; **P < 0.01; ***P < 0.001) in the comparison with the experimental groups by one-way ANOVA. Raw blots are presented in Supplementary Data 1.

    Journal: Scientific reports

    Article Title: Combined effect of the pro-apoptotic rhTRAIL protein and HSV-1 virus in head and neck cancer cell lines.

    doi: 10.1038/s41598-023-44888-9

    Figure Lengend Snippet: Figure 2. Expression analysis of apoptosis-associated proteins in the HCB289 cell line after 24 h of exposure with rhTRAIL ligand, WT HSV-1 and in combination. (A) and (B) detection and quantification of proteins after treatment. Results are expressed as mean percentage ± standard deviation of relative expression of cleaved protein relative to control (considering 100% expression) and normalized by the portion of total protein (non- cleaved). Data represent the average of three independent assays. The asterisks indicate statistical significance (*P < 0.05; **P < 0.01; ***P < 0.001) in the comparison with the experimental groups by one-way ANOVA. Raw blots are presented in Supplementary Data 1.

    Article Snippet: :(0123456789) Scientific Reports | (2023) 13:18023 | https://doi.org/10.1038/s41598-023-44888-9 treated with rhTRAIL (#375-TL, R&D Systems, Minneapolis, MN, EUA) at 100 ng/mL, HSV-1 MOI 0.2 and/ or HSV-1 MOI 1.

    Techniques: Expressing, Standard Deviation, Control, Comparison

    Figure 3. Expression analysis of apoptosis-associated proteins in the UD-SCC-2 cell line after 24 h of exposure with rhTRAIL ligand, WT HSV-1 and in combination. (A) and (B) detection and quantification of proteins after treatment. Results are expressed as mean percentage ± standard deviation of relative expression of cleaved protein relative to control (considering 100% expression) and normalized by the portion of total protein (non- cleaved). Data represent the average of three independent assays. The asterisks indicate statistical significance (*P < 0.05; **P < 0.01; ***P < 0.001) in the comparison with the experimental groups by one-way ANOVA. Raw blots are presented in Supplementary Data 2.

    Journal: Scientific reports

    Article Title: Combined effect of the pro-apoptotic rhTRAIL protein and HSV-1 virus in head and neck cancer cell lines.

    doi: 10.1038/s41598-023-44888-9

    Figure Lengend Snippet: Figure 3. Expression analysis of apoptosis-associated proteins in the UD-SCC-2 cell line after 24 h of exposure with rhTRAIL ligand, WT HSV-1 and in combination. (A) and (B) detection and quantification of proteins after treatment. Results are expressed as mean percentage ± standard deviation of relative expression of cleaved protein relative to control (considering 100% expression) and normalized by the portion of total protein (non- cleaved). Data represent the average of three independent assays. The asterisks indicate statistical significance (*P < 0.05; **P < 0.01; ***P < 0.001) in the comparison with the experimental groups by one-way ANOVA. Raw blots are presented in Supplementary Data 2.

    Article Snippet: :(0123456789) Scientific Reports | (2023) 13:18023 | https://doi.org/10.1038/s41598-023-44888-9 treated with rhTRAIL (#375-TL, R&D Systems, Minneapolis, MN, EUA) at 100 ng/mL, HSV-1 MOI 0.2 and/ or HSV-1 MOI 1.

    Techniques: Expressing, Standard Deviation, Control, Comparison

    Figure 4. Expression analysis of apoptosis-associated proteins in the HCB289 cell line after 48 h of exposure with rhTRAIL ligand, WT HSV-1 and in combination. (A) and (B) detection and quantification of proteins after treatment. Results are expressed as mean percentage ± standard deviation of relative expression of cleaved protein relative to control (considering 100% expression) and normalized by the portion of total protein (non- cleaved). Data represent the average of two independent assays. The asterisks indicate statistical significance (*P < 0.05) in the comparison with the experimental groups by one-way ANOVA. Raw blots are presented in Supplementary Data 3.

    Journal: Scientific reports

    Article Title: Combined effect of the pro-apoptotic rhTRAIL protein and HSV-1 virus in head and neck cancer cell lines.

    doi: 10.1038/s41598-023-44888-9

    Figure Lengend Snippet: Figure 4. Expression analysis of apoptosis-associated proteins in the HCB289 cell line after 48 h of exposure with rhTRAIL ligand, WT HSV-1 and in combination. (A) and (B) detection and quantification of proteins after treatment. Results are expressed as mean percentage ± standard deviation of relative expression of cleaved protein relative to control (considering 100% expression) and normalized by the portion of total protein (non- cleaved). Data represent the average of two independent assays. The asterisks indicate statistical significance (*P < 0.05) in the comparison with the experimental groups by one-way ANOVA. Raw blots are presented in Supplementary Data 3.

    Article Snippet: :(0123456789) Scientific Reports | (2023) 13:18023 | https://doi.org/10.1038/s41598-023-44888-9 treated with rhTRAIL (#375-TL, R&D Systems, Minneapolis, MN, EUA) at 100 ng/mL, HSV-1 MOI 0.2 and/ or HSV-1 MOI 1.

    Techniques: Expressing, Standard Deviation, Control, Comparison

    Figure 5. Expression analysis of apoptosis-associated proteins in the UD-SCC-2 cell line after 48 h of exposure with rhTRAIL ligand, WT HSV-1 and in combination. (A) and (B) detection and quantification of proteins after treatment. Results are expressed as mean percentage ± standard deviation of relative expression of cleaved protein relative to control (considering 100% expression) and normalized by the portion of total protein (non- cleaved). Data represent the average of two independent assays. The asterisks indicate statistical significance (*P < 0.05) in the comparison with the experimental groups by one-way ANOVA. Raw blots are presented in Supplementary Data 4.

    Journal: Scientific reports

    Article Title: Combined effect of the pro-apoptotic rhTRAIL protein and HSV-1 virus in head and neck cancer cell lines.

    doi: 10.1038/s41598-023-44888-9

    Figure Lengend Snippet: Figure 5. Expression analysis of apoptosis-associated proteins in the UD-SCC-2 cell line after 48 h of exposure with rhTRAIL ligand, WT HSV-1 and in combination. (A) and (B) detection and quantification of proteins after treatment. Results are expressed as mean percentage ± standard deviation of relative expression of cleaved protein relative to control (considering 100% expression) and normalized by the portion of total protein (non- cleaved). Data represent the average of two independent assays. The asterisks indicate statistical significance (*P < 0.05) in the comparison with the experimental groups by one-way ANOVA. Raw blots are presented in Supplementary Data 4.

    Article Snippet: :(0123456789) Scientific Reports | (2023) 13:18023 | https://doi.org/10.1038/s41598-023-44888-9 treated with rhTRAIL (#375-TL, R&D Systems, Minneapolis, MN, EUA) at 100 ng/mL, HSV-1 MOI 0.2 and/ or HSV-1 MOI 1.

    Techniques: Expressing, Standard Deviation, Control, Comparison

    Figure 6. Flow cytometry apoptosis analysis after treatment with rhTRAIL ligand, WT HSV-1 and in combination. A and B) Analysis of HCB289 cell line after 24 and 48 h of treatment exposure. C and D) Analysis of UD-SCC-2 cell line after 24 and 48 h of treatment exposure. Results are expressed as mean percentage ± standard deviation of the cell death rate. Data represent the average of three independent assays. The asterisks indicate statistical significance (*P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.001) in the comparison with the experimental groups by one-way ANOVA.

    Journal: Scientific reports

    Article Title: Combined effect of the pro-apoptotic rhTRAIL protein and HSV-1 virus in head and neck cancer cell lines.

    doi: 10.1038/s41598-023-44888-9

    Figure Lengend Snippet: Figure 6. Flow cytometry apoptosis analysis after treatment with rhTRAIL ligand, WT HSV-1 and in combination. A and B) Analysis of HCB289 cell line after 24 and 48 h of treatment exposure. C and D) Analysis of UD-SCC-2 cell line after 24 and 48 h of treatment exposure. Results are expressed as mean percentage ± standard deviation of the cell death rate. Data represent the average of three independent assays. The asterisks indicate statistical significance (*P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.001) in the comparison with the experimental groups by one-way ANOVA.

    Article Snippet: :(0123456789) Scientific Reports | (2023) 13:18023 | https://doi.org/10.1038/s41598-023-44888-9 treated with rhTRAIL (#375-TL, R&D Systems, Minneapolis, MN, EUA) at 100 ng/mL, HSV-1 MOI 0.2 and/ or HSV-1 MOI 1.

    Techniques: Flow Cytometry, Standard Deviation, Comparison

    Figure 7. DR-5 expression analysis in the HCB289 cell line after treatment with rhTRAIL ligand, WT-HSV-1 and combination. (A) and (B) Detection and quantification of the receptor after 24 h of exposure treatment. (C) and (D) Detection and quantification of the receptor after 48 h of exposure treatment. Results are expressed as mean percentage ± standard deviation of relative expression of cleaved protein relative to control (considering 100% expression) and normalized by the protein α-tubulin. Data represent the average of two independent. Raw blots are presented in Supplementary Data 5.

    Journal: Scientific reports

    Article Title: Combined effect of the pro-apoptotic rhTRAIL protein and HSV-1 virus in head and neck cancer cell lines.

    doi: 10.1038/s41598-023-44888-9

    Figure Lengend Snippet: Figure 7. DR-5 expression analysis in the HCB289 cell line after treatment with rhTRAIL ligand, WT-HSV-1 and combination. (A) and (B) Detection and quantification of the receptor after 24 h of exposure treatment. (C) and (D) Detection and quantification of the receptor after 48 h of exposure treatment. Results are expressed as mean percentage ± standard deviation of relative expression of cleaved protein relative to control (considering 100% expression) and normalized by the protein α-tubulin. Data represent the average of two independent. Raw blots are presented in Supplementary Data 5.

    Article Snippet: :(0123456789) Scientific Reports | (2023) 13:18023 | https://doi.org/10.1038/s41598-023-44888-9 treated with rhTRAIL (#375-TL, R&D Systems, Minneapolis, MN, EUA) at 100 ng/mL, HSV-1 MOI 0.2 and/ or HSV-1 MOI 1.

    Techniques: Expressing, Standard Deviation, Control

    Figure 8. DR-5 expression analysis in the UD-SCC-2 cell line after treatment with rhTRAIL ligand, WT-HSV-1 and combination. (A) and (B) Detection and quantification of the receptor after 24 h of exposure treatment. (C) and (D) Detection and quantification of the receptor after 48 h of exposure treatment. Results are expressed as mean percentage ± standard deviation of relative expression of cleaved protein relative to control (considering 100% expression) and normalized by the protein α-tubulin. Data represent the average of two independent assays. Raw blots are presented in Supplementary Data 6.

    Journal: Scientific reports

    Article Title: Combined effect of the pro-apoptotic rhTRAIL protein and HSV-1 virus in head and neck cancer cell lines.

    doi: 10.1038/s41598-023-44888-9

    Figure Lengend Snippet: Figure 8. DR-5 expression analysis in the UD-SCC-2 cell line after treatment with rhTRAIL ligand, WT-HSV-1 and combination. (A) and (B) Detection and quantification of the receptor after 24 h of exposure treatment. (C) and (D) Detection and quantification of the receptor after 48 h of exposure treatment. Results are expressed as mean percentage ± standard deviation of relative expression of cleaved protein relative to control (considering 100% expression) and normalized by the protein α-tubulin. Data represent the average of two independent assays. Raw blots are presented in Supplementary Data 6.

    Article Snippet: :(0123456789) Scientific Reports | (2023) 13:18023 | https://doi.org/10.1038/s41598-023-44888-9 treated with rhTRAIL (#375-TL, R&D Systems, Minneapolis, MN, EUA) at 100 ng/mL, HSV-1 MOI 0.2 and/ or HSV-1 MOI 1.

    Techniques: Expressing, Standard Deviation, Control

    IFNα is cytotoxic to a subset of bladder cancer cell lines in multiple contexts (A) Schematic of adenoviral tool vectors. The Ad-IFNα2b vector includes hIFNα2b driven by a CMV promoter inserted into the E1 region and GFP driven by the RSV promoter inserted into the E3 region. The Ad-GFP vector includes an empty E1 region and GFP driven by the RSV promoter inserted into the E3 region. Both tool viruses lack viral E1 and E3. (B–G) Cells were exposed to (B) 100,000 U/mL rhIFNα2b, (C) 50 ng/mL TRAIL, (D) Ad-IFNα2b (MOI = 100), (E) Ad-GFP (MOI = 100) and conditioned media (CM) produced by (F) Ad-IFNα2b or (G) Ad-GFP transduced SV-HUC-1 cells. Cytotoxicity is reported as the relative fraction of dead cells after 48 h of treatment. Results are presented as mean ± SD from independent experiments performed in triplicate; N = 2 or 3 for Ad-GFP, N = 3 for all other treatments. (H) Pairwise correlation analysis was performed for all treatments and the Pearson correlation coefficient was determined. Bold indicates P < 0.05. (I) Cells were exposed to Ad-IFNα2b, Ad-GFP, or Ad-empty (MOI = 100 for all); cytotoxicity is reported as the relative fraction of dead cells after 48 h of treatment. Ad, adenovirus vector; CMV, cytomegalovirus; GFP, green fluorescent protein; rhIFNα2b, recombinant human interferon alpha 2b, rhTRAIL, recombinant human TNF-related apoptosis-inducing ligand; RSV, respiratory syncytial virus; SV40 Poly(A), simian virus 40 polyadenylated tail.

    Journal: Molecular Therapy Oncolytics

    Article Title: Molecular characterization of type I IFN-induced cytotoxicity in bladder cancer cells reveals biomarkers of resistance

    doi: 10.1016/j.omto.2021.11.006

    Figure Lengend Snippet: IFNα is cytotoxic to a subset of bladder cancer cell lines in multiple contexts (A) Schematic of adenoviral tool vectors. The Ad-IFNα2b vector includes hIFNα2b driven by a CMV promoter inserted into the E1 region and GFP driven by the RSV promoter inserted into the E3 region. The Ad-GFP vector includes an empty E1 region and GFP driven by the RSV promoter inserted into the E3 region. Both tool viruses lack viral E1 and E3. (B–G) Cells were exposed to (B) 100,000 U/mL rhIFNα2b, (C) 50 ng/mL TRAIL, (D) Ad-IFNα2b (MOI = 100), (E) Ad-GFP (MOI = 100) and conditioned media (CM) produced by (F) Ad-IFNα2b or (G) Ad-GFP transduced SV-HUC-1 cells. Cytotoxicity is reported as the relative fraction of dead cells after 48 h of treatment. Results are presented as mean ± SD from independent experiments performed in triplicate; N = 2 or 3 for Ad-GFP, N = 3 for all other treatments. (H) Pairwise correlation analysis was performed for all treatments and the Pearson correlation coefficient was determined. Bold indicates P < 0.05. (I) Cells were exposed to Ad-IFNα2b, Ad-GFP, or Ad-empty (MOI = 100 for all); cytotoxicity is reported as the relative fraction of dead cells after 48 h of treatment. Ad, adenovirus vector; CMV, cytomegalovirus; GFP, green fluorescent protein; rhIFNα2b, recombinant human interferon alpha 2b, rhTRAIL, recombinant human TNF-related apoptosis-inducing ligand; RSV, respiratory syncytial virus; SV40 Poly(A), simian virus 40 polyadenylated tail.

    Article Snippet: The following other reagents were used in this study: rhIFNα2b (Stem Cell Technologies, 78,077), palbociclib (Cayman, 16,273), rhTRAIL (R&D 375-TL).

    Techniques: Plasmid Preparation, Produced, Recombinant, Virus